Tailored therapy to hemodynamic goals for advanced heart failure. - Wikidata - wikimedia - TriplyDB

Tailored therapy to hemodynamic goals for advanced heart failure.

Tailored therapy to hemodynamic goals for advanced heart failure.

http://www.wikidata.org/entity/Q33997965

about

Natriuretic peptides for acute heart failure Nitrates for acute heart failure syndromes Natriuretic peptides for acute heart failure Nitrates for acute heart failure Case report: exercise in a patient with acute decompensated heart failure receiving positive inotropic therapy.Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan?Management of acute decompensated heart failure in the emergency department.Guidelines for acute decompensated heart failure treatment.BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases.Development of implantable devices for continuous ambulatory monitoring of central hemodynamic values in heart failure patients.Regional hippocampal damage in heart failure.Ultrafiltration for acute decompensated heart failure.A practical guide for ultrafiltration in acute decompensated heart failure.Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patient-parts 1-6.A rational approach to assess volume status in patients with decompensated heart failure.Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure.The role of intravenous vasodilators in acute heart failure management.Management of acute decompensated heart failure: treatment, controversy, and future directions.NT-proBNP and BNP: biomarkers for heart failure management.Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.Impaired cerebellar and limbic responses to the valsalva maneuver in heart failure.Combination of Hydralazine and Isosorbide-Dinitrate in the Treatment of Patients with Heart Failure with Reduced Ejection Fraction.Noninvasive hemodynamic monitoring in heart failure: utilization of impedance cardiography.Implant experience with an implantable hemodynamic monitor for the management of symptomatic heart failure.Feasibility and accuracy of transthoracic Doppler echocardiographic estimation of pulmonary capillary wedge pressure applying different methods.

P2860

Q24194433-6DCDA577-8D4B-435B-A029-E2B028F3B817 Q24200550-4E760513-0253-45A7-A9F6-F2427FFB0A2A Q24245105-185D364E-93E5-4831-A946-D803BD851D6B Q24245410-0342C5EA-D6E7-4600-B78A-7653BB05DE6E Q35016321-C3DEA311-2A97-42AB-A0BB-5360D4915676 Q35057072-53EC0D1F-5048-4509-938B-043E7BD45471 Q35561935-3B24F813-0698-482C-95A6-FBE7EEBE78C9 Q35675111-B91A5DCB-9CAA-4646-9852-46F0F7C7B972 Q35987052-5B7DCE31-78D9-4ECB-A72B-B337E3836BCF Q36162547-6D9D5317-D8BE-463C-8909-4A907D782BD5 Q36295925-C1192EDC-0E1C-4BCA-AAB3-FFFC19AA3395 Q36315167-E82B3C89-C76D-4B10-9010-26E89AAB1E65 Q37133900-4780F79C-CF79-42BD-A5A1-BE015CC6F943 Q37461040-5A3B99ED-E0E6-4E9E-BEF9-9349DA5F4408 Q37988380-E0C3F99A-3C4C-4F1C-A6E5-5BBF0EE0121C Q38009708-38D53807-D75D-4596-8F29-5EA1FA5BDC46 Q38237577-7E3427B3-293A-4302-8D6B-19A3A9DF4A0D Q40304351-34A2132B-62D1-4520-B900-FF7FCBCEBCED Q40528924-5416A83B-C88D-45C0-885D-A8364899A24A Q43716652-F6664FFE-F036-4F70-93AB-CF34ABB7ABF5 Q46579921-D7DFCED7-D7CD-42DE-B41A-5DEDFD3EB6B4 Q46859898-F7CEA62F-E5DF-44CA-A95F-DB345529DA6D Q50732340-B431E92B-7FB4-4C39-B254-358939CD2338 Q51370803-8D152C88-538A-470F-AB2E-5C15EE2973A5 Q52053680-092B292C-A16E-49EE-8071-95746256C16A

P2860

Tailored therapy to hemodynamic goals for advanced heart failure.

http://www.wikidata.org/entity/Q33997965

description

1999 nî lūn-bûn

@nan

1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Tailored therapy to hemodynamic goals for advanced heart failure.

@ast

Tailored therapy to hemodynamic goals for advanced heart failure.

@en

type

label

Tailored therapy to hemodynamic goals for advanced heart failure.

@ast

Tailored therapy to hemodynamic goals for advanced heart failure.

@en

prefLabel

Tailored therapy to hemodynamic goals for advanced heart failure.

@ast

Tailored therapy to hemodynamic goals for advanced heart failure.

@en

P1433

Q33997965-817CC47F-30E0-494E-8F58-DF1CCC915290

P1476

Q33997965-7D4F9193-5A88-46FD-9259-125BE16B1E82

P2093

Q33997965-D23FA86B-D8AB-4FB5-A889-5B67D7D58691

P2860

Q33997965-135F367E-5D86-4868-9F2B-637E8CAC8835

Q33997965-2AD197B4-D60D-48D7-B5D6-68A48328BEF8

Q33997965-59804B83-5F12-4A78-B4DF-F965588CF0C3

Q33997965-6441D475-1F3B-4F59-9F60-4F19FF0BA52F

Q33997965-8A825390-0370-468F-B17E-625348436BF7

Q33997965-9A2EA210-4AE1-45AA-BF45-740437BD2502

Q33997965-AA2B9F40-1A9D-490C-8926-8F7C59297356

Q33997965-B46295B2-8420-46AA-A804-241A83AA8423

Q33997965-B495FB93-6C6E-4E52-941C-2C632BC638CC

Q33997965-B733E78E-7EA6-46FD-93E9-F33542F5EB83

P304

Q33997965-E26ABE2B-255F-4E7A-82B0-1E0874F026D4

P31

Q33997965-B5C9AE99-D3AD-4D29-8424-355F6BA824A8

P356

Q33997965-FBFC7952-F8FE-424B-907E-23EA2E1F694E

P433

Q33997965-D2BCA3B4-9080-45F3-B83C-7D336A12E584

P478

Q33997965-946F3E31-CCF9-4A84-978F-DF9D7670CF70

P577

Q33997965-B60FF0A3-13E6-48A0-BFAC-C93869D0E59F

P5875

Q33997965-02807927-5516-4D31-8540-238E0B5F2DE0

P698

Q33997965-541407C1-CA9A-4425-B857-5DFA0ECC805D

P921

Q33997965-1667CF78-3008-436F-A8B6-1F9CE5DC4D9C

P356

S1388-9842(99)00015-X

P1433

European Journal of Heart Failure

P1476

Tailored therapy to hemodynamic goals for advanced heart failure.

@en

P2093

Stevenson LW

http://www.w3.org/2001/XMLSchema#string

P2860

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators.

Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell.

Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure.

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy.

Prevalence and hemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

P304

251-257

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1388-9842(99)00015-X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

1999-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12384354

http://www.w3.org/2001/XMLSchema#string

P698

10935671

http://www.w3.org/2001/XMLSchema#string

P921